Moderna Inc. Banner Image

Moderna Inc.

  • Ticker MRNA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Moderna Inc. Logo Image
  • 501-1000 Employees
  • Based in Cambridge, Massachusetts
Moderna scientists designed the company’s prophylactic vaccines modality to prevent infectious diseases. More than 1,900 participants, prior to enrolling the Phase 3 study of mRNA-1273, have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Clinical data demonstrate that Moderna’s proprietary vaccine technologyMore has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical experience across Phase 1 studies, the company designated prophylactic vaccines a core modality and is working to accelerate the development of its vaccine pipeline.
Moderna Inc.

Most Recent Responsibility Report

Moderna Inc.
Our service enables potential investors to review the most recent and archived Moderna Inc. Sustainability Report, Moderna Inc. Corporate Social Responsibility Report, Moderna Inc. CSR Report, Moderna Inc. Corporate Responsibility, Moderna Inc. CR Report, Moderna Inc. Citizenship Report, Moderna Inc. ESG Report, and Moderna Inc. Environmental Report online.